What topics does this cannabis study cover?

This study covers research on: Pain.

Where was this research published?

Published in European journal of pain (London, England) on February 1, 2026.

Fruit Flies Reveal CBD's Promising Pain-Relieving Potential

Q: What did this research study find?

In a groundbreaking study, researchers have used *Drosophila melanogaster* (fruit flies) to explore chronic pain mechanisms and the potential of *cannabidiol* (CBD) as an analgesic. The study focused on a specific genetic mutation (parabss1) that causes **heightened sensitivity to pain stimuli**, pr

The parabss1 Drosophila melanogaster as Model for Chronic Nociception: Insights Into Cannabidiol Analgesic Effects.

European journal of pain (London, England) • February 1, 2026 • Moderately Relevant

🤖

AI Summary

In a groundbreaking study, researchers have used Drosophila melanogaster (fruit flies) to explore chronic pain mechanisms and the potential of cannabidiol (CBD) as an analgesic. The study focused on a specific genetic mutation (parabss1) that causes heightened sensitivity to pain stimuli, providing a novel model for understanding chronic pain at the molecular level.

The research revealed that CBD significantly increased pain response latency in both mutant and wild-type fruit flies, suggesting a promising role for cannabinoids in pain management. By using the parabss1 mutant, scientists created an innovative and cost-effective platform for screening potential pain treatments, particularly those targeting sodium channel dysfunctions. This approach offers a unique alternative to traditional animal models, potentially accelerating the development of new pain therapies.

Importantly, the study highlighted the translational potential of using fruit flies to investigate complex pain mechanisms. The strong genetic homology between fruit fly sodium channels and human NaV1.7 channels provides valuable insights into how genetic mutations contribute to chronic pain. This research not only advances our understanding of pain pathways but also demonstrates cannabidiol's potential as a versatile therapeutic compound for managing chronic pain conditions.

📄 Original Abstract

Chronic pain, which is often unrelated to ongoing injury, is poorly understood and difficult to treat. Genetic studies have identified voltage-gated sodium (Nav) channels, particularly gain-of-function mutations such as L858F and R1150W in human NaV1.7, as involved in the development of chronic pain. A chronic pain model was proposed in Drosophila using the parabss1 mutant. Behavioural chemical nociceptive assay was conducted, and sensitivity was pharmacologically tested with carbamazepine and cannabidiol to assess the model's validity for analgesic screening. Sequence alignment and 3D structural modelling revealed strong homology between human Nav1.7 and the para gene, though no structural alterations were observed between the parabss1 allele and the wild-type allele. Functionally, parabss1 larvae exhibited enhanced sensitivity to chemical, nociceptive stimuli compared to w1118 larvae. Furthermore, carbamazepine increased response latency in w1118; however, parabss1 showed a time and dose-dependent response to this treatment. Oral administration of cannabidiol significantly increased latency to chemical stimuli in both genotypes, supporting cannabidiol's modulatory role in nociceptive circuits. These findings validate the parabss1 mutant as a tractable in vivo platform for chronic nociception studies and pharmacological screening. The parabss1 mutant demonstrates heightened chemical nociception, resistance to carbamazepine and sensitivity to cannabidiol, thereby validating it as a pertinent Drosophila model for chronic pain. This model facilitates the screening of candidate analgesics targeting sodium channel dysfunctions in an in vivo setting, thereby demonstrating translational potential. This study proposes the Drosophila melanogaster parabss1 mutant as a valid and manageable in vivo model for chronic nociception. By exhibiting selective hypersensitivity, resistance to conventional treatment and sensitivity to cannabidiol, this model provides a cost-effective and ethically favourable platform for the preclinical screening of novel analgesics that target sodium channel dysfunctions. This study opens a new avenue for translational pain research and aligns with the ongoing demand for alternative animal models in pain therapeutic development.

Paper Type

📄 Research

Publication

Journal: European journal of pain (London, England)
Published: February 1, 2026
PMID: 41589562
DOI: 10.1002/ejp.70225

Authors (8)

Serena Mares Malta Laboratory of Genetics, Institute of Biotechnology, Federal University of Uberlandia, Uberlandia, Minas Gerais, Brazil.
Lucas Ian Veloso Correia Laboratory of Nanobiotechnology, Institute of Biotechnology, Federal University of Uberlandia, Uberlandia, Minas Gerais, Brazil.
Alexandre Souza Marquez Laboratory of Genetics, Institute of Biotechnology, Federal University of Uberlandia, Uberlandia, Minas Gerais, Brazil.
Lucas Matos Martins Bernardes Laboratory of Genetics, Institute of Biotechnology, Federal University of Uberlandia, Uberlandia, Minas Gerais, Brazil.
John George Howland Department of Anatomy, Physiology and Pharmacology, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.
+3 more authors

MeSH Keywords

Animals Cannabidiol Drosophila melanogaster Nociception Disease Models, Animal Analgesics Chronic Pain Drosophila Proteins Carbamazepine NAV1.7 Voltage-Gated Sodium Channel